Amini: They play a significant role in how we treat metastatic lung cancer. All patients with stage IV disease should have molecular testing performed.Ho: Molecular alterations have become a central ...
Amini: From a radiation standpoint, this has changed the landscape of our field. A large proportion of my practice is stage IV disease, where patients who are on these excellent systemic therapies are ...
According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have ...
Outcomes of patients with concurrent chronic lymphocytic leukemia and non-small cell lung carcinoma. Circulating tumor DNA as a prognostic biomarker for long-term survival in de-novo oligometastatic ...
Lung cancer is one of the kinds of cancer that is most likely to spread to the brain. Approximately 20 percent of lung cancer patients develop brain metastases. And roughly 10 to 20 percent of people ...
The primary battleground in the competition for lung cancer treatments is shifting toward "brain metastasis." This shift comes as new research has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results